Gliclazide
Who holds supplier records for Gliclazide? 12 organisations hold a current record for Gliclazide: an active US FDA Type II Drug Master File or a CEP. A further 2 organisations have only historical (inactive) DMF filings. 11 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (6), Italy (2), China (2) and France (1); not recorded for 1.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Gliclazide: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/gliclazide
Reading the evidence
- 12 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 9 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (12)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Gliclazide. Country is the organisation's recorded country, not necessarily the manufacturing site.
- COSMA SPAItaly Company GMP cert on recordActive DMF 25538 · latest filing Dec 2011
- IndiaCEP Company GMP cert on record
- IndiaCEP Company GMP cert on record
- IndiaCEP Company GMP cert on record
- IndiaCEP Company GMP cert on record
- IndiaCEP Company GMP cert on record
- ItalyCEP Company GMP cert on record
- FranceCEP
- SHANDONG HAIYOU FREDA PHARMACEUTICAL CO LTDCEP
- Shandong Keyuan Pharmaceutical Co.,Ltd.ChinaCEP
- IndiaCEP Company GMP cert on record
- Zhejiang Jiuzhou Pharmaceutical Co., Ltd.ChinaCEP Company GMP cert on record
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (11)
Certificates of Suitability on the EDQM register for Gliclazide, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 17 certificates in total, including withdrawn, expired, suspended and repeat certificates.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| SOHAN HEALTHCARE PRIVATE LIMITED Pune | IN | CEP 2020-237 - Rev 02 Gliclazide | Aug 2026 | Inspected Feb 2024 Hungary |
| SHANDONG HAIYOU FREDA PHARMACEUTICAL CO. LTD. Linyi | CN | CEP 2024-434 - Rev 00 Gliclazide | Oct 2025 | — |
| GRANULES INDIA LIMITED Hyderabad | IN | CEP 2017-240 - Rev 03 Gliclazide | Aug 2025 | — |
| BAL PHARMA LIMITED Bengaluru | IN | CEP 2013-039 - Rev 04 Gliclazide, AP | Jul 2025 | — |
| ANUH PHARMA LTD. Mumbai | IN | CEP 2021-398 - Rev 02 Gliclazide | Jul 2025 | — |
| INDOCO REMEDIES LIMITED Mumbai | IN | CEP 2010-202 - Rev 01 Gliclazide | Apr 2025 | — |
| AMI LIFESCIENCES PRIVATE LIMITED Karakhadi | IN | CEP 2021-465 - Rev 00 Gliclazide | Feb 2024 | Inspected Oct 2025 Slovakia |
| OLON S.P.A. Rodano | IT | R1-CEP 2004-134 - Rev 05 Gliclazide | Jul 2021 | — |
| ORIL INDUSTRIE Bolbec | FR | R1-CEP 2005-182 - Rev 01 Gliclazide | Feb 2020 | — |
| Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Taizhou City | CN | R1-CEP 2003-138 - Rev 01 Gliclazide | Dec 2014 | — |
| SHANDONG KEYUAN PHARMACEUTICAL CO., LTD. Jinan | CN | R1-CEP 2006-007 - Rev 01 Gliclazide | May 2013 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (2)
Organisations whose Type II DMFs for Gliclazide are no longer active. These show a past filing, not current supply.
Show all 2 historical records
- SHANDONG FANGMING PHARMACEUTICAL GROUP CO LTDInactive DMF 25574 · filed Nov 2011
- NINGBO DOUBLE SUN PHARMACEUTICAL CO LTDInactive DMF 19921 · filed Aug 2006
Overview
Gliclazide is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL427216).
Chemical identity
- IUPAC name
- 1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea
- Canonical SMILES
- CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2
- InChIKey
- BOVGTQGAOIONJV-UHFFFAOYSA-N
- Synonyms
- Bilxona, Dacadis mr, Diaglyk, Diamicron, Diamicron mr, Edicil, Gliclazida, Gliclazide, Glimicron, Glimil, J3.151H, Nazdol mr
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Gliclazide?
12 organisations hold an active US FDA Type II Drug Master File or a CEP for Gliclazide: COSMA SPA (Italy), AMI LIFESCIENCES PRIVATE LTD (India), Anuh Pharma Limited (India), Bal Pharma Limited (India), Granules India Limited (India), INDOCO REMEDIES LTD (India), OLON SPA (Italy) and ORIL INDUSTRIE (France), and 4 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Gliclazide Drug Master Files are active?
COSMA SPA (DMF 25538). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Gliclazide records mean?
2 organisations have only inactive Type II DMFs for Gliclazide. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Gliclazide have a European Certificate of Suitability?
Yes. 11 organisations hold a valid CEP for Gliclazide on the EDQM register, including SOHAN HEALTHCARE PRIVATE LIMITED Pune (IN), SHANDONG HAIYOU FREDA PHARMACEUTICAL CO. LTD. Linyi (CN), GRANULES INDIA LIMITED Hyderabad (IN), BAL PHARMA LIMITED Bengaluru (IN), ANUH PHARMA LTD. Mumbai (IN) and INDOCO REMEDIES LIMITED Mumbai (IN) and 5 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
How do I qualify a Gliclazide supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Gliclazide?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.